{"title":"减肥药物可改善酒精使用障碍患者的治疗效果","authors":"","doi":"10.1002/pu.31274","DOIUrl":null,"url":null,"abstract":"<p>Use of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide was associated with reduced risk of alcohol-related hospitalization in patients with alcohol use disorder (AUD), a cohort study has found. Both semaglutide and the GLP-1 receptor agonist liraglutide were associated with lower risk of hospitalization than use of medication treatments for AUD. Study results were published online Nov. 13, 2024, in <i>JAMA Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 3","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Weight-loss drugs improve outcomes in patients with alcohol use disorder\",\"authors\":\"\",\"doi\":\"10.1002/pu.31274\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Use of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide was associated with reduced risk of alcohol-related hospitalization in patients with alcohol use disorder (AUD), a cohort study has found. Both semaglutide and the GLP-1 receptor agonist liraglutide were associated with lower risk of hospitalization than use of medication treatments for AUD. Study results were published online Nov. 13, 2024, in <i>JAMA Psychiatry</i>.</p>\",\"PeriodicalId\":22275,\"journal\":{\"name\":\"The Brown University Psychopharmacology Update\",\"volume\":\"36 3\",\"pages\":\"1-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pu.31274\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31274","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Weight-loss drugs improve outcomes in patients with alcohol use disorder
Use of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide was associated with reduced risk of alcohol-related hospitalization in patients with alcohol use disorder (AUD), a cohort study has found. Both semaglutide and the GLP-1 receptor agonist liraglutide were associated with lower risk of hospitalization than use of medication treatments for AUD. Study results were published online Nov. 13, 2024, in JAMA Psychiatry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
